Pediatrix Medical Group stock hits 52-week high at 17.7 USD

Pediatrix Medical Group Inc. stock reached a new 52-week high, closing at 17.7 USD, with a strong financial health score of "GREAT" according to InvestingPro analysis. This milestone marks a significant achievement for the company, reflecting a robust performance over the past year. The stock has delivered impressive returns, gaining 29.88% year-to-date and trading at an attractive P/E ratio of 13.65. According to InvestingPro’s Fair Value analysis, the stock appears undervalued, suggesting potential upside remains. This upward trajectory in Pediatrix’s stock price highlights its resilience and potential for continued growth in the healthcare sector. For deeper insights into Pediatrix’s financial health and growth prospects, InvestingPro offers comprehensive analysis with 8 additional ProTips and a detailed research report.

In other recent news, Pediatrix Medical Group reported impressive earnings for the second quarter of 2025, surpassing analysts’ expectations. The company achieved an earnings per share of $0.53, exceeding the forecasted $0.42, and reported revenue of $468.84 million, slightly above the anticipated $464.37 million. Additionally, the Board of Directors has authorized a $250 million share repurchase program, which will be executed over the next three years based on several factors, including market conditions and business requirements.

In analyst updates, Leerink Partners raised its price target for Pediatrix Medical Group to $17.00 from $14.50, maintaining a Market Perform rating. UBS also increased its price target to $16.50 from $16.00, following the company’s strong second-quarter performance. Jefferies, however, lowered its price target to $19.00 from $21.00, citing concerns over eAPTC, despite recognizing the company’s consistent quarterly EBITDA beats. These developments reflect the varied perspectives among analysts concerning Pediatrix Medical Group’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.